{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:05:11Z","timestamp":1778893511550,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12185-020-02898-7","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T10:05:46Z","timestamp":1591610746000},"page":"377-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-305X","authenticated-orcid":false,"given":"Ivan","family":"Kre\u010dak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mori\u0107 Peri\u0107","family":"Martina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Zekanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017eena","family":"Coha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velka","family":"Gveri\u0107-Kre\u010dak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"4","key":"2898_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.seminhematol.2018.04.005","volume":"55","author":"S Ferreira Cristina","year":"2018","unstructured":"Ferreira Cristina S, Polo B, Lacerda JF. Somatic mutations in Philadelphia chromosome-negative myeloproliferative neoplasms. Semin Hematol. 2018;55(4):215\u201322.","journal-title":"Semin Hematol"},{"key":"2898_CR2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91:390\u20134.","journal-title":"Am J Hematol"},{"key":"2898_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25303","volume":"94","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94:133\u201343.","journal-title":"Am J Hematol"},{"key":"2898_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"2898_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneph.2010.143","volume":"6","author":"TB Dr\u00fceke","year":"2010","unstructured":"Dr\u00fceke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6:723\u201335.","journal-title":"Nat Rev Nephrol"},{"key":"2898_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1681\/ASN.2007030308","volume":"19","author":"K Wattanakit","year":"2008","unstructured":"Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19:135\u201340.","journal-title":"J Am Soc Nephrol"},{"key":"2898_CR7","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1093\/ndt\/gfq179","volume":"25","author":"AR Folsom","year":"2010","unstructured":"Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M. Chronic kidney disease and venous thromboembolism: a prospective study. Atherosclerosis Risk in Communities Study. Nephrol Dial Transplant. 2010;25:3296\u2013301.","journal-title":"Nephrol Dial Transplant"},{"key":"2898_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","volume":"91","author":"RO Mathew","year":"2017","unstructured":"Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91:797\u2013807.","journal-title":"Kidney Int"},{"key":"2898_CR9","first-page":"2918","volume":"18","author":"M Liu","year":"2014","unstructured":"Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci. 2014;18:2918\u201326.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2898_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fcell.2019.00314","volume":"7","author":"M Provenzano","year":"2019","unstructured":"Provenzano M, Coppolino G, De Nicola L, Serra R, Garofalo C, Andreucci M, et al. Unraveling cardiovascular risk in renal patients: a new take on old tale. Front Cell Dev Biol. 2019;7:314.","journal-title":"Front Cell Dev Biol"},{"issue":"27","key":"2898_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"1","key":"2898_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/kisup.2012.67","volume":"3","author":"Kidney Disease Improving Global Outcomes Work Group","year":"2013","unstructured":"Kidney Disease Improving Global Outcomes Work Group. Chapter 4:Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl. 2013;3(1):91\u2013111.","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"2898_CR13","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","volume":"42","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050\u201365.","journal-title":"Hypertension"},{"key":"2898_CR14","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.3324\/haematol.2018.208876","volume":"104","author":"Y Fukuda","year":"2019","unstructured":"Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, et al. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica. 2019;104:e506\u2013e509509.","journal-title":"Haematologica"},{"key":"2898_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","volume":"38","author":"AS Christensen","year":"2014","unstructured":"Christensen AS, M\u00f8ller JB, Hasselbalch HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38:490\u20135.","journal-title":"Leuk Res"},{"key":"2898_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3904\/kjim.2016.263","volume":"33","author":"SW Baek","year":"2018","unstructured":"Baek SW, Young Moon J, Ryu H, Choi YS, Song IK, Lee HY, et al. Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. Korean J Intern Med. 2018;33:790\u20137.","journal-title":"Korean J Intern Med"},{"key":"2898_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ki.2011.147","volume":"80","author":"SM Said","year":"2011","unstructured":"Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80:753\u20139.","journal-title":"Kidney Int"},{"key":"2898_CR18","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau M, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2898_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2898_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.444","volume":"85","author":"A Levin","year":"2014","unstructured":"Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49\u201361.","journal-title":"Kidney Int"},{"key":"2898_CR21","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219\u201325.","journal-title":"Blood"},{"issue":"213","key":"2898_CR22","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.1970.03170390053014","volume":"28","author":"GL Bailey","year":"1970","unstructured":"Bailey GL, Katz AI, Hampers CL, Merrill JP. Alterations in serum enzymes in chronic renal failure. JAMA. 1970;28(213):2263\u20135.","journal-title":"JAMA"},{"key":"2898_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.0954-6820.1968.tb02430.x","volume":"184","author":"VK Nielsen","year":"1968","unstructured":"Nielsen VK, Kemp E, Laursen T. Lactic dehydrogenase in kidney tissue and renal disease. Adaptive change of the synthesis in acute failure. Acta Med Scand. 1968;184:109\u201319.","journal-title":"Acta Med Scand"},{"key":"2898_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"2898_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"2898_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00277-019-03708-9","volume":"98","author":"P Strati","year":"2019","unstructured":"Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, et al. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol. 2019;98:1611\u20136.","journal-title":"Ann Hematol"},{"key":"2898_CR27","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1182\/blood.V118.21.5151.5151","volume":"118","author":"YK Kim","year":"2011","unstructured":"Kim YK, Bae SY, Yu L, Kim NY, Lee SR, Ahn JS, et al. Renal adverse effect of anagrelide in patients with myeloproliferative neoplasms. Blood. 2011;118:5151.","journal-title":"Blood"},{"key":"2898_CR28","first-page":"2073","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Chronic Kidney Dis Prognosis Consort Lancet. 2010;375:2073\u201381.","journal-title":"Chronic Kidney Dis Prognosis Consort Lancet"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02898-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02898-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02898-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:23:04Z","timestamp":1623108184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02898-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2898"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02898-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"28 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}